SCHEMBL201537

SCHEMBL201537

C/C=C/OCc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.48
IDO1 P14902 1/20 0.44
AGXT P21549 1/20 0.43
ALDH1A1 P00352 3/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
MAPT P10636 2/20 0.41
MAPK1 P28482 2/20 0.41
TDP1 Q9NUW8 2/20 0.41
TP53 P04637 1/20 0.39
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
CA9 Q16790 2/20 0.38
SLC6A2 P23975 2/20 0.38
SLC6A3 Q01959 2/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
PTGS1 P23219 1/20 0.38
CYP2C19 P33261 1/20 0.38
PTGS2 P35354 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL201538 1.00 TSHR (0.48) TSHRIDO1AGXTALDH1A1L3MBTL1
SCHEMBL6731394 1.00 TSHR (0.48) TSHRIDO1AGXTALDH1A1L3MBTL1
SCHEMBL29284778 0.89 TDP1 (0.43) TSHRIDO1AGXTALDH1A1L3MBTL1
SCHEMBL27509183 0.85 TSHR (0.57) TSHRIDO1AGXTALDH1A1L3MBTL1
Phosphoric Acid Monomethyl Ester SCHEMBL6825269 0.84 TSHR (0.47) TSHRALDH1A1RAB9A
SCHEMBL58206 0.81 TSHR (0.52) TSHRIDO1AGXTALDH1A1L3MBTL1
SCHEMBL16594360 0.80 TSHR (0.46) TSHRIDO1AGXTALDH1A1L3MBTL1
SCHEMBL16594361 0.80 TSHR (0.46) TSHRIDO1AGXTALDH1A1L3MBTL1
SCHEMBL11798275 0.79 TSHR (0.50) TSHRIDO1AGXTALDH1A1L3MBTL1
SCHEMBL7717208 0.78 IDO1 (0.46) TSHRIDO1AGXTALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3572402-B1 LINKED CYCLIC COMPOUND AS CASPASE INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) 2022-05-04 EP disclosed
US-20190111044-A1 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS Prosetta Antiviral, Inc. 2019-04-18 US disclosed
EP-1603414-B1 ELECTROPROCESSED PHENOLIC MATERIALS AND METHODS UNIV VIRGINIA COMMONWEALTH (US) 2017-05-03 EP disclosed
US-9196860-B2 Compounds for triplet-triplet annihilation upconversion UNIVERSAL DISPLAY CORPORATION (US) 2015-11-24 US disclosed
US-20140151646-A1 COMPOUNDS FOR TRIPLET-TRIPLET ANNIHILATION UPCONVERSION UNIVERSAL DISPLAY CORPORATION 2014-06-05 US disclosed
US-8088804-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2012-01-03 US disclosed
US-8012399-B2 Formation of nano-or micro-scale phenolic fibers via electrospinning PHILIP MORRIS USA INC. (US) 2011-09-06 US disclosed
EP-2338878-A2 N-hydroxyamide derivatives possessing antibacterial activity Vicuron Pharmaceuticals, Inc. (US) 2011-06-29 EP disclosed
US-7691843-B2 N-hydroxyamide derivatives possessing antibacterial activity PFIZER INC. (US) 2010-04-06 US disclosed
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. 2010-01-28 US disclosed
EP-1963262-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2008-09-03 EP disclosed
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity VICURON HOLDINGS LLC 2008-03-06 US disclosed
WO-2007069020-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2007-06-21 WO disclosed
EP-1539744-A4 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARM INC (US) 2007-06-06 EP disclosed
US-20070035055-A1 Electroprocessed phenolic materials and methods PHILIP MORRIS USA INC. 2007-02-15 US disclosed
US-20070020625-A1 Sequence of the photorhabdus luminescens strain tt01 genome and uses DUCHAUD ERIC 2007-01-25 US disclosed
EP-1603414-A1 ELECTROPROCESSED PHENOLIC MATERIALS AND METHODS Virginia Commonwealth University (US) 2005-12-14 EP disclosed
EP-1539744-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-06-15 EP disclosed
WO-2004080217-A1 ELECTROPROCESSED PHENOLIC MATERIALS AND METHODS VIRGINIA COMMONWEATH UNIVERSITY (US) 2004-09-23 WO disclosed
WO-2004007444-A2 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190111044-A1 2-PHENETHENYLTETRAHYDRO ISOQUINOLINES USEFUL AS ANTI-HIV COMPOUNDS MAVS, EIF2AK2, POLRMT TSHR 4860/4885IDO1 135/4885AGXT 4118/4885
US-20100022605-A1 N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY NAAA, HDHD5, HACL2 TSHR 3341/4885IDO1 1620/4885AGXT 1307/4885
US-20080058304-A1 N-hydroxyamide derivatives possessing antibacterial activity AMDHD2, OGA, ENGASE TSHR 3540/4885IDO1 390/4885AGXT 520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.